Tesamorelin U.S. label context · version 1
This page preserves this version's wording and source pins. Open the current profile →
What does the U.S. product label say?
Egrifta SV · Read September 15, 2026 · Preserved label summary 1
Which population and use does the label cover?
The label covers reduction of excess abdominal fat in adults with HIV and lipodystrophy. It explicitly excludes weight-loss management and says long-term cardiovascular safety has not been established. Label: 1 ↗
Which safety limits matter?
Contraindications include disruption of the hypothalamic-pituitary axis, active malignancy, hypersensitivity and pregnancy. Warnings address neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity and acute critical illness. The label says effects of prolonged IGF-1 elevation are unknown. Label: 4, 5 ↗
Label edition and source pins
U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.
EGRIFTA SV (tesamorelin) kit · SPL version 9 · published 2026-07-31
Label ZIP SHA-256: 2208a57e39a937407fe40c3d00ff1f8547a7a33e87685d40205cfaba9137cc6c. Extracted XML SHA-256: 280dc13506741337de1fe23ec2d53b3c65241abd9501425611ff106932ca714d.